Company Overview

Board of Directors

JEFFREY BIRD, M.D., Ph.D.
Sutter Hill Ventures

Jeffrey Bird focuses on healthcare, including biotechnology and medical devices. He is currently a board member at AkaRx, Inc. (cancer and hematology therapeutics), Macusight (ophthalmic therapeutics), NuGen Technologies (research reagents), Portola Pharmaceuticals (cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), Roxro Pharma (pain therapeutics) and Xoft Microtube (cancer radiation devices). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics), and Barrx (gastrointestinal devices). Dr. Bird was previously senior vice president, business operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He received his B.S. from Stanford in 1982, a Ph.D. in cancer biology in 1988 and a M.D. in 1992 from Stanford Medical School.

FARAH CHAMPSI
Alta Partners

Farah Champsi is a director at Alta Partners and joined the firm in 2000, prior to the formation of Alta BioPharma II. She is currently on the board of directors at Portola Pharmaceuticals, Aerovance, Excaliard Pharmaceuticals, Myocor, Sanarus Medical, Trevena, and serves as the chairperson of the board for Zelos Therapeutics. Farah also led Alta’s investment in Agensys. Prior investments include Cytokinetics, Esperion, Orphan Medical and Renovis. She focuses her efforts on biopharmaceutical and medical technology companies. Prior to Alta, Farah was an investment banker at Robertson Stephens & Company between 1987 and 1999, where she focused on biotechnology and other life sciences companies. She was elected a general partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street. She holds an M.B.A. from Stanford University and a B.A. in Economics from Smith College.

ALAN D. FRAZIER
Frazier Healthcare Ventures

Alan Frazier is the founder and managing partner of Frazier Healthcare Ventures, which over the past 16 years has raised seven venture capital funds representing $1.8 billion in committed capital and has invested in over 100 emerging life science companies. Mr. Frazier assists with evaluating biopharmaceutical, medical device and growth equity investments. He has been integrally involved in growing several successful early-stage life science companies into national prominence—such as Immunex, Affymax and Affymetrix—and he has secured premiere deal flow through early-stage investments such as Tularik and CV Therapeutics on behalf of Frazier Healthcare. Currently, Mr. Frazier serves on the boards of Alexza Pharmaceuticals, Cadence Pharmaceuticals, Calistoga Pharmaceuticals, Calixa Therapeutics, Informed Medical Communications, and Portola Pharmaceuticals.

NICHOLAS GALAKATOS, Ph.D.
MPM BioVentures II and BioVentures III, L.L.C.

Nick Galakatos is a co-founder and Managing Director of Clarus Ventures. He has been a venture capital investor since 1992, initially at Venrock Associates and then at MPM Capital where he was general partner of the BioVentures II and III funds. From 1997-2000 Nick was vice president, new business and a member of the management team at Millennium Pharmaceuticals. During that time he co-founded Millennium Predictive Medicine and TransForm, where he also was the chairman and founding CEO. Nick entered the venture capital business after being head of molecular biology research at Ciba (presently Novartis). He holds a B.A degree in chemistry from Reed College, a Ph.D. degree in organic chemistry from MIT, and performed postdoctoral studies in molecular biology at Harvard Medical School. Nick is the lead director at Affymax, and a member of the board of directors of Aerovance, Alinea Pharmaceuticals, Aveo Pharmaceuticals, Portola Pharmaceuticals and Taligen Therapeutics.

JEAN GEORGE
ATV

Jean George joined Advanced Technology Ventures in 2002. She is a general partner and serves as the firm’s east coast lead for healthcare investments. She accesses new deals in the life sciences and therapeutic device markets, identifying innovations viable for commercialization. On behalf of ATV, she led investments in Critical Therapeutics, Five Prime Therapeutics, Hydra Biosciences, Hypnion, Proteolix and Portola Pharmaceuticals. She currently is a board member of Acceleron Pharmaceuticals, Critical Therapeutics, Hypnion, Juniper Medical, Proteolix and Portola. Ms. George brings more than 20 years of biopharmaceutical industry experience to ATV, including 10 years at Genzyme Corporation. She holds an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.

RUSSELL HIRSCH, M.D., Ph.D.
Prospect Ventures

Russell Hirsch is a managing director of Prospect Venture Partners. Prior to establishing Prospect Venture Partners II and III, he was a member of the health care technology group at Mayfield. He joined Mayfield in 1992, serving as a venture partner from 1993 to 1994 and as a general partner from 1995-2000. Dr. Hirsch played a key role in Mayfield's investment activities in the biotechnology and medical device sectors. As an associate, he participated actively in the incubation of Millennium Pharmaceuticals and as a general partner he was responsible for the incubation of Intuitive Surgical Devices, both of which are now publicly traded. Dr. Hirsch holds an M.D. and Ph.D. in biochemistry from the University of California, San Francisco and a B.A. in chemistry from the University of Chicago.

CHARLES HOMCY, M.D.
President and Chief Executive Officer, Portola Pharmaceuticals

Charles Homcy has served as president and chief executive officer since he co-founded Portola Pharmaceuticals, Inc. in 2003. Previously, he was president, research and development at Millennium following Millennium’s acquisition of COR Therapeutics in 2002. Dr. Homcy joined COR in 1995 as executive vice president, research and development, and he served as a director of the company from 1998 to 2002. He has been a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco VA Hospital since 1997. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Dr. Homcy serves on the board of directors of Geron Corporation. Dr. Homcy received his A.B. and M.D. degrees from Johns Hopkins University.

PEGGY PHILLIPS
Independent

Peggy Phillips is the former chief operating officer of Immunex, Inc. She served as COO from 1999 until the company was acquired by Amgen in 2002. She was responsible for all development, manufacturing, sales and marketing activities. Prior to becoming COO, Ms. Phillips served as the general manager for Enbrel, overseeing all phases of product development. She was a member of the Immunex board of directors from 1996 to 2002. Currently, Ms. Phillips serves on the board of directors of Portola Pharmaceuticals, Dynavax and the United States Naval Academy Foundation.

HOLLINGS C. RENTON
Independent

Hollings C. Renton previously served as president and chief executive officer, director and chairman of the board of Onyx Pharmaceuticals, Inc. Prior to joining Onyx, he was the president and chief operating officer of Chiron Corporation. He assumed that position on Chiron’s acquisition of Cetus Corporation, where he had been president and chief operating officer and previously served as chief financial officer. He currently serves as chairman of the board of Affymax, Inc. and a member of the boards of directors of Rigel Pharmaceuticals, Cepheid Corporation and the Special Olympics of Northern California. Mr. Renton holds a B.S. in mathematics from Colorado State University and M.B.A. from the University of Michigan.

H. WARD WOLFF
Independent

Ward Wolff has served as executive vice president and chief financial officer of Sangamo BioSciences since December 2007. Mr. Wolff was formerly with Nuvelo, Inc., where he served as senior vice president, finance and chief financial officer until its restructuring in August 2007. Prior to joining Nuvelo, he was chief financial officer and senior vice president, finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as senior vice president and chief financial officer of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. Mr. Wolff received a B.A. degree in economics from the University of California at Berkeley and an M.B.A. degree from Harvard Business School.

Back to top